Effects of insulin and octreotide on memory and growth hormone in Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 18, Issue 3, 2009, Pages 595-602

  Watson, G Stennis ^a,b   Baker, Laura D ^a,b   Cholerton, Brenna A ^a,b   Rhoads, Kristoffer W ^a,b,c   Merriam, George R ^a,b   Schellenberg, Gerard D ^a,b,d   Asthana, Sanjay ^e   Cherrier, Monique ^a,b   Craft, Suzanne ^a,b  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c VIRGINIA MASON MEDICAL CENTER   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Acetylcholine; Alzheimer's disease (AD); Apolipoprotein E (APOE); Growth hormone (GH); Insulin; Memory; Mild cognitive impairment (MCI); Octreotide; Somatostatin

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E EPSILON4; GLUCOSE; GROWTH HORMONE; INSULIN; OCTREOTIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE SEVERITY; FACILITATION; FEMALE; GROWTH HORMONE BLOOD LEVEL; HUMAN; MALE; MEMORY; MEMORY DISORDER; PRIORITY JOURNAL; RATING SCALE; RECALL;

EID: 75149132487     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2009-1165     Document Type: Article

References (33)

1. Beal MF, Mazurek MF, Tran VT, Chattha G, Bird ED, Martin JB (1985) Reduced numbers of somatostatin receptors in the cerebral cortex in Alzheimer's disease. Science 229, 289-291.
2. Craft S,Watson GS (2004) Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol 3, 169-178.
3. Craft S, Asthana S, Newcomer JW, Wilkinson CW, Matos IT, Baker LD, Cherrier M, Lofgreen C, Latendresse S, Petrova A, Plymate S, Raskind M, Grimwood K, Veith RC (1999) Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose. Arch Gen Psychiatry 56, 1135-1140.
4. Craft S, Asthana S, Cook DG, Baker LD, Cherrier M, Purganan K, Wait C, Petrova A, Latendresse S, Watson GS, Newcomer JW, Schellenberg GD, Krohn AJ (2003) Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype. Psychoneuroendocrinology 28, 809-822.
5. Chan-Palay V (1987) Somatostatin immunoreactive neurons in the human hippocampus and cortex shown by immunogold/ silver intensification on vibratome sections: coexistence with neuropeptide Y neurons, and effects in Alzheimer-type dementia. J Comp Neurol 260, 201-223.
6. Dutar P, Vaillend C, Viollet C, Billard JM, Potier B, Carlo AS, Ungerer A, Epelbaum J (2002) Spatial learning and synaptic hippocampal plasticity in type 2 somatostatin receptor knockout mice. Neuroscience 112, 455-466.
7. Tokita K, Inoue T, Yamazaki S, Wang F, Yamaji T, Matsuoka N, Mutoh S (2005) FK962, a novel enhancer of somatostatin release, exerts cognitive-enhancing actions in rats. Eur J Pharmacol 527, 111-120.
8. Ramos B, Baglietto-Vargas D, Rio JC, Moreno-Gonzalez I, Santa-Maria C, Jimenez S, Caballero C, Lopez-Tellez JF, Khan ZU, Ruano D, Gutierrez A, Vitorica J (2006) Early neuropathology of somatostatin/NPY GABAergic cells in the hippocampus of a PS1xAPP transgenic model of Alzheimer's disease. Neurobiol Aging 27, 1658-1672.
9. Kumar U (2005) Expression of somatostatin receptor subtypes (SSTR1-5) in Alzheimer's disease brain: an immunohistochemical analysis. Neuroscience 134, 525-538.
10. Watson GS, Cholerton BA, Reger MA, Baker LD, Plymate SR, Asthana S, Fishel MA, Kulstad JJ, Green PS, Cook DG, Kahn SE, Keeling ML, Craft S (2005) Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 13, 950-958.
11. Krentz AJ, Boyle PJ, Macdonald LM, Schade DS (1994) Octreotide: a long-acting inhibitor of endogenous hormone secretion for human metabolic investigations. Metabolism 43, 24-31.
12. Watson GS, Craft S (2004) Modulation of memory by insulin and glucose: neuropsychological observations in Alzheimer's disease. Eur J Pharmacol 490, 97-113.
13. Jaehde U, Masereeuw R, De Boer AG, Fricker G, Nagelkerke JF, Vonderscher J, Breimer DD (1994) Quantification and visualization of the transport of octreotide, a somatostatin analogue, across monolayers of cerebrovascular endothelial cells. Pharm Res 11, 442-448.
14. Zipser BD, Johanson CE, Gonzalez L, Berzin TM, Tavares R, Hulette CM, Vitek MP, Hovanesian V, Stopa EG (2006) Microvascular injury and blood-brain barrier leakage in Alzheimer's disease. Neurobiol Aging 28, 977-986.
15. Karalis K, Mastorakos G, Chrousos GP, Tolis G (1994) Somatostatin analogues suppress the inflammatory reaction in vivo. J Clin Invest 93, 2000-2006.
16. Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A, Pollmacher T (2001) Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 58, 445-452.
17. Grouselle D, Winsky-Sommerer R, David JP, Delacourte A, Dournaud P, Epelbaum J (1998) Loss of somatostatin-like immunoreactivity in the frontal cortex of Alzheimer patients carrying the apolipoprotein epsilon 4 allele. Neurosci Lett 255, 21-24.
18. Petersen RC (2004) Mild cognitive impairment as a diagnostic entity. J Intern Med 256, 183-194.
19. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
20. Craft S, Asthana S, Schellenberg G, Cherrier M, Baker LD, Newcomer J, Plymate S, Latendresse S, Petrova A, Raskind M, Peskind E, Lofgreen C, Grimwood K (1999) Insulin metabolism in Alzheimer's disease differs according to apolipoprotein E genotype and gender. Neuroendocrinology 70, 146-152.
21. Petrides M, Milner B (1982) Deficits on subject-ordered tasks after frontal-and temporal-lobe lesions in man. Neuropsychologia 20, 249-262.
22. Kahn SE, Leonetti DL, Prigeon RL, Boyko EJ, Bergstrom RW, Fujimoto WY (1995) Relationship of proinsulin and insulin with noninsulin-dependent diabetes mellitus and coronary heart disease in Japanese-American men: impact of obesity-clinical research center study. J Clin Endocrinol Metab 80, 1399-1406.
23. Craft S, Asthana S, Schellenberg G, Baker L, Cherrier M, Boyt AA, Martins RN, Raskind M, Peskind E, Plymate S (2000) Insulin effects on glucose metabolism, memory, and plasma amyloid precursor protein in Alzheimer's disease differ according to apolipoprotein-E genotype. Ann N Y Acad Sci 903, 222-228.
24. Heilig M, Sjogren M, Blennow K, Ekman R, Wallin A (1995) Cerebrospinal fluid neuropeptides in Alzheimer's disease and vascular dementia. Biol Psychiatry 38, 210-216.
25. Reinikainen KJ, Riekkinen PJ, Jolkkonen J, Kosma VM, Soininen H (1987) Decreased somatostatin-like immunoreactivity in cerebral cortex and cerebrospinal fluid in Alzheimer's disease. Brain Res 402, 103-108. (Pubitemid 17006934)
26. Nakata A, Saito H, Nishiyama N (1996) Facilitatory role of somatostatin via muscarinic cholinergic system in the generation of long-term potentiation in the rat dentate gyrus in vivo. Brain Res 723, 135-140.
27. Matsuoka N, Maeda N, Yamaguchi I, SatohM(1994) Possible involvement of brain somatostatin in the memory formation of rats and the cognitive enhancing action of FR121196 in passive avoidance task. Brain Res 642, 11-19.
28. Araujo DM, Lapchak PA, Collier B, Quirion R (1990) Evidence that somatostatin enhances endogenous acetylcholine release in the rat hippocampus. J Neurochem 55, 1546-1555.
29. Matsuoka N, Kaneko S, Satoh M (1991) Somatostatin augments long-term potentiation of the mossy fiber-CA3 system in guinea-pig hippocampal slices. Brain Res 553, 188-194.
30. Poirier J, Delisle MC, Quirion R, Aubert I, Farlow M, Lahiri D, Hui S, Bertrand P, Nalbantoglu J, Gilfix BM, Gauthier S (1995) Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Natl Acad Sci U S A 92, 12260-12264.
31. Degn KB, Brock B, Juhl CB, Djurhuus CB, Grubert J, Kim D, Han J, Taylor K, Fineman M, Schmitz O(2004) Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucosedependent insulin secretion and counterregulation during hypoglycemia. Diabetes 53, 2397-2403.
32. Meneilly GS, Cheung E, Tuokko H (1994) Altered responses to hypoglycemia of healthy elderly people. J Clin Endocrinol Metab 78, 1341-1348.
33. Galassetti P, Davis SN (2000) Effects of insulin per se on neuroendocrine and metabolic counter-regulatory responses to hypoglycaemia. Clin Sci (Lond) 99, 351-362.